Review: Comparison of Extended Half-Life (EHL) to Standard Half-Life (SHL) Replacement Therapy in Hemophilia - Real-World Evidence Study

Abstract

Hemophilia is a common hereditary coagulation blood disorder due to the deficiency in clotting factor activities. Among all treatments, standard half-life (SHL) and extended half-life (EHL) factor replacement products are the most commonly used. This study aimed to review real-world evidence on the comparison of EHL and SHL. A literature search was conducted in PubMed and google scholar published from 2017 to 2021. There were ten articles that met the criteria. Based on the results extracted, the total proportion of patients using EHL factor concentrates for both on-demand, and prophylactic factor replacement therapy increased. Recent evidence reveals that EHL may reduce the number of infusions, increase factor trough levels, and substantially decrease the annual bleeding rate. Efficacy-wise, EHLs unquestionably perform better than SHLs; however, the EHL products seem too expensive to be utilized as the primary standard of care for hemophilia. The economic aspect of replacement factor switching still requires more in-depth studies